Legacy Direct Thrombin Inhibitors — Desirudin J0838, Lepirudin (withdrawn 2012), Fondaparinux J1652

About the legacy DTI class FDA labels + market history verified May 2026

The direct thrombin inhibitor (DTI) class entered clinical practice in the late 1990s and early 2000s as the first heparin-independent anticoagulants. The recombinant hirudins — lepirudin (Refludan, 1998) and desirudin (Iprivask, 2003) — were yeast-derived, bivalent thrombin binders modeled on the leech-saliva protein. They were positioned for HIT therapy (lepirudin), post-orthopedic VTE prophylaxis (desirudin), and as the parenteral alternative to heparin for patients with HIT history.

Between 2010 and 2014 the FDA approved three direct oral anticoagulants — dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) — for VTE prophylaxis after orthopedic surgery, VTE treatment, and non-valvular atrial fibrillation. The DOACs collapsed the parenteral-hirudin market: oral administration, no coagulation lab monitoring, and fixed dosing eliminated the practical advantages of SC/IV agents for outpatient and post-discharge use. Lepirudin (Refludan) was withdrawn from the US market in April 2012 for commercial reasons (not safety); the manufacturer (Bayer / Berlex) cited declining demand. Desirudin (Iprivask) remains on the FDA Orange Book through Bausch Health Companies after multiple license transfers (originator Aventis Behring → Schering → Canyon → Marathon → Bausch) but with substantially reduced clinical volume.

Fondaparinux (Arixtra) is included on this rollup despite not being a true DTI. It is a synthetic pentasaccharide that selectively inhibits factor Xa via antithrombin — mechanistically distinct from the hirudins and from argatroban/bivalirudin. It is included because (a) billers regularly confuse it with the DTI class given overlapping HIT-context discussion, and (b) it is contraindicated in active HIT per the FDA label and HIT guidelines despite not cross-reacting with HIT antibodies in vitro — a clinically important and frequently misunderstood nuance. Fondaparinux is itself currently available as both branded Arixtra and multi-source generic.

The page is built to handle three specific biller scenarios: (1) a desirudin claim from a Bausch Iprivask encounter that needs HIT-history or post-op surgical encounter ICD-10 substantiation; (2) a retrospective audit of a pre-2012 lepirudin claim; and (3) the most common scenario — a fondaparinux line submitted under a HIT diagnosis that needs to be redirected back to argatroban or bivalirudin. Active-HIT inpatient and PCI use is covered on the dedicated argatroban and bivalirudin pages.

DTI landscape map — active dedicated pages vs this rollup CMS HCPCS verified May 2026

The HIT / DTI billing space splits across two active dedicated pages (argatroban, bivalirudin) and this rollup for the legacy / edge-case set.

Billers seeing an anticoagulant J-code under a HIT or VTE diagnosis should first identify which of the four functional categories the drug falls in. The active-use DTIs have their own dedicated reference pages with full ASP, dosing math, and PA workflows; the legacy / edge-case agents are consolidated on this rollup.

Per-drug dosing FDA labels verified May 2026

Three separate dosing regimens. Desirudin SC fixed-interval; lepirudin historical continuous IV titrated; fondaparinux SC daily.

Desirudin / Iprivask — FDA-labeled regimen

Lepirudin / Refludan — historical regimen (drug withdrawn April 2012)

For continuous infusion historical lepirudin claims, the billable unit count was cumulative mg infused over the encounter, calculated from pump records (mg/kg/hr × weight × hours). Inpatient lepirudin was DRG-bundled; outpatient/observation lepirudin would have billed under J3490 unclassified with Refludan NDC.

Fondaparinux / Arixtra — FDA-labeled regimens (NOT for HIT)

Unit math — fondaparinux J1652 conversion

Fondaparinux J1652 is "Injection, fondaparinux sodium, 0.5 mg." One unit = 0.5 mg, NOT 1 mg. Mis-conversion is a common error.

NDC reference FDA NDC Directory verified May 2026

Per-drug NDC entries. Lepirudin NDCs included for retrospective audit only — product not currently distributed.

Administration codes CPT verified May 2026

Two of three drugs on this rollup are SC injections (96372). Lepirudin (historical) was continuous IV (96365/96366).

Modifiers CMS verified May 2026

JW / JZ — single-dose vial waste reporting

Per CMS's July 2023 single-dose container policy (CR 12056), one of JZ (no waste) or JW (waste) is required on claims for drugs supplied in single-dose containers. Whether JZ/JW applies to a drug on this rollup depends on the specific product dispensed.

Worked example — desirudin reduced-dose JW

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the injection (e.g., hematology consult for HIT history before first desirudin dose). Routine pre-injection clinical assessment is bundled into the admin code.

340B modifiers (JG, TB)

For 340B-acquired desirudin or fondaparinux, follow your MAC's current 340B modifier policy. Hospital outpatient departments billing under OPPS are subject to specific 340B reporting requirements; office-based 340B reporting varies by MAC.

ICD-10-CM FY2026 verified May 2026

Three different diagnostic contexts. Desirudin = post-orthopedic surgical encounter or HIT-history. Lepirudin (historical) = active HIT with thrombocytopenia. Fondaparinux = VTE prophylaxis or treatment in non-HIT populations.

Site of care & place of service Verified May 2026

The drugs on this rollup are SC injections (desirudin, fondaparinux) or historical IV infusion (lepirudin). Desirudin's labeled use case — post-orthopedic DVT prophylaxis — is almost entirely inpatient surgical / observation followed by outpatient or self-administration through the 9-12 day course. Fondaparinux similarly straddles inpatient initiation and outpatient continuation. Historical lepirudin was inpatient ICU only.

Claim form field mapping CMS verified May 2026

Most desirudin/fondaparinux medical-benefit claims are observation/HOPD UB-04. Office/infusion-suite claims (rare) follow CMS-1500.

Payer policy snapshot Reviewed May 2026

Step therapy from DOACs is the dominant theme. Desirudin requires HIT-history or DOAC-failure documentation; fondaparinux requires heparin/DOAC-failure. Lepirudin has no current coverage pathway (drug withdrawn).

Lepirudin (historical) coverage

No current coverage exists because the drug is not in US distribution post-April-2012. Pre-2012 claims were covered under Part B / Medicare Advantage / commercial inpatient bundles with appropriate D69.5x or equivalent thrombocytopenia ICD-9 (pre-2015) or ICD-10 (2015-2012) coding. Retrospective audits should verify dates of service against the withdrawal date.

Off-label / society guidance

The CHEST / ACCP 2018 HIT guidelines and ASH 2018 HIT guidelines list argatroban and bivalirudin as first-line non-heparin anticoagulants for active HIT. Lepirudin (when available) and danaparoid (no longer marketed in US) were historically alternatives. Fondaparinux is mentioned in the guidelines as a controversial off-label option for HIT only in narrow circumstances with hematology oversight — not a first-line agent and not a substitute for direct thrombin inhibitor therapy. Desirudin has no role in the active-HIT-treatment guidelines.

Medicare reimbursement CMS Q2 2026 (live for J1652)

Quarterly ASP from CMS Part B Drug Pricing File. J1652 (fondaparinux) actively published; J0838 (desirudin) is NOT in the current CMS ASP file — verify MAC invoice pricing.

Coverage

No NCD specific to fondaparinux, desirudin, or the legacy DTI class. Coverage falls under MAC LCDs for therapeutic injectable drug administration and the standard Part B drug coverage framework. All MACs cover J1652 for FDA-approved VTE indications and J0838 for post-hip-replacement DVT prophylaxis with appropriate ICD-10 substantiation. Lepirudin has no current coverage (withdrawn).

Code history

• J0838 — permanent code, "Injection, desirudin, per 1 mg" (added with Iprivask FDA approval in 2003)
• J1652 — permanent code, "Injection, fondaparinux sodium, 0.5 mg" (added with Arixtra FDA approval in 2001; retained for generic fondaparinux post-2011)
• Lepirudin — no permanent J-code ever assigned; historically billed under J3490 unclassified with Refludan NDC + invoice. Drug withdrawn from US market April 2012.

Patient assistance Verified May 2026

• Bausch Health Patient Assistance Program (desirudin / Iprivask): Bausch Health maintains a Patient Assistance Program for uninsured / underinsured patients meeting income criteria. Phone: 800-321-4576. Enrollment via prescriber form + income documentation. Eligibility typically requires income at or below 400% FPL for branded specialty products; verify current criteria with the program coordinator.
• Mylan / Viatris (Arixtra branded fondaparinux): Mylan Cares Patient Assistance for uninsured patients meeting income criteria. Phone: 800-796-9526. Generic fondaparinux is widely available at low cash price through GoodRx-style discount programs and most Part D / commercial pharmacy benefit copays are nominal.
• Foundation backup: PAN Foundation (panfoundation.org), HealthWell Foundation (healthwellfoundation.org), and Patient Advocate Foundation (patientadvocate.org) may have applicable funds for VTE prophylaxis / treatment populations on intermittent basis — verify fund status at time of enrollment.
• Lepirudin / Refludan: No current PAP — product withdrawn April 2012. Bayer / Berlex programs closed at withdrawal.
• 340B-acquired pricing: For DSH / CAH / rural hospitals participating in 340B, fondaparinux is 340B-eligible at substantial discounts. Desirudin 340B eligibility varies by institutional contract.
• Specialty pharmacy navigation: Outpatient post-discharge desirudin and fondaparinux self-injection prescriptions typically route through specialty pharmacy; the SP coordinator can enroll the patient in manufacturer copay assistance and foundation grants in parallel with PA submission.

Common denials & how to fix them Reviewed May 2026

Frequently asked questions

Why is this called a “legacy” rollup?

All three drugs covered on this page (desirudin, lepirudin, fondaparinux) have been largely displaced by direct oral anticoagulants (DOACs — apixaban, rivaroxaban, dabigatran, edoxaban) for general VTE prophylaxis and treatment populations from roughly 2014 onward. Oral dosing, no routine coagulation monitoring, and fixed-dose simplicity collapsed the use case for parenteral hirudins outside of two narrow niches: desirudin for SC post-orthopedic HIT-history prophylaxis at HIT-experienced centers, and historical lepirudin claim audits (withdrawn from US market April 2012). Fondaparinux remains available for non-HIT VTE prophylaxis and treatment but is contraindicated in active HIT. Active HIT therapy lives on the dedicated argatroban and bivalirudin pages.

Desirudin vs argatroban — when do I use which?

Desirudin (Iprivask, J0838) is FDA-approved for prophylaxis of DVT in patients undergoing elective hip replacement surgery; dosing is 15 mg SC every 12 hours for 9-12 days, started before surgery. Practical use post-DOACs is narrow: patients with documented prior HIT who need surgical prophylaxis but cannot receive heparin or DOACs — and even there, fondaparinux (off-label) or argatroban bridging is more common. Argatroban (J0883/J0884) is the active-treatment workhorse for established HIT in inpatient settings — continuous IV titrated to aPTT 1.5-3x baseline. Desirudin is fixed-dose SC; argatroban is continuous IV titrated to lab. The two drugs are NOT interchangeable across indications and the J-codes are distinct. See /drugs/argatroban for full HIT treatment workflow.

Fondaparinux CONTRAINDICATED in HIT — why?

Per the FDA label for Arixtra (fondaparinux), HIT is NOT a labeled indication and the drug should not be administered for treatment of HIT thrombosis. Although fondaparinux is a synthetic pentasaccharide that targets factor Xa indirectly via antithrombin and does not cross-react with HIT antibodies in standard PF4 ELISA assays in vitro, there are published case reports of fondaparinux-associated thrombocytopenia and fondaparinux-induced thrombosis in HIT patients. CHEST/ACCP and ASH HIT guidelines list argatroban, bivalirudin, and historically danaparoid as the labeled non-heparin anticoagulants for HIT; fondaparinux is at best a second-tier off-label option with explicit medical-necessity justification. Billing J1652 against a D75.82 (HIT) primary diagnosis triggers payer review and frequently denies.

Lepirudin — is it still available?

No. Lepirudin (Refludan, Bayer / Berlex) was withdrawn from the US market in April 2012 by the manufacturer for commercial reasons (not safety). The HCPCS J3490 (unclassified) or historical J-codes appearing on legacy claims should be researched against the date of service — lepirudin administered after the April 2012 withdrawal date will not have valid US distribution and cannot be re-supplied. Billers handling old-claim audits or denied retrospective adjustments may still see lepirudin entries on charts pre-2012; ensure the date of service predates the withdrawal and that pharmacy records substantiate actual administration. Lepirudin is also discontinued in most ex-US markets.

DOAC vs DTI for general VTE prophylaxis — what changed?

Between 2010 and 2014 the FDA approved apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa) for VTE prophylaxis after orthopedic surgery, VTE treatment, and non-valvular atrial fibrillation. These oral agents collapsed the post-discharge prophylaxis market that desirudin had been positioned for — no SC injection burden, no INR or aPTT monitoring, fixed dosing, and at-home administration. Parenteral DTI use compressed back into the inpatient acute HIT space (argatroban, bivalirudin) and the cath lab. By 2018 desirudin volumes in CMS Part B claims had fallen by more than 90% from peak. The Iprivask brand has had multiple license transfers reflecting the small remaining market.

Post-orthopedic HIT prophylaxis options — what is the workflow today?

For a patient with prior HIT history who needs post-orthopedic-surgery DVT prophylaxis, the typical 2026 workflow is: (1) confirm HIT history with prior PF4 ELISA result or chart documentation; (2) confer with hematology pre-op; (3) choose between fondaparinux 2.5 mg SC daily (off-label in HIT history — some institutional protocols allow with HIT-experienced hematology oversight), apixaban 2.5 mg PO BID (off-label in HIT history but pragmatic given DOAC track record), or desirudin 15 mg SC q12h x 9-12 days (the labeled option but supply, cost, and 30-min-pre-injection reconstitution discourages routine use); and (4) document the HIT history (Z86.79 or D75.82) plus the rationale. Desirudin remains the only FDA-labeled SC DTI for this specific indication but is rarely the first practical choice.

Bausch Health Iprivask supply status?

Iprivask (desirudin) is currently US-licensed to Bausch Health Companies after several prior license transfers (originator: Aventis Behring / Schering; later Canyon Pharmaceuticals; later Marathon Pharmaceuticals). The product remains on the FDA Orange Book and is commercially available in the US but with limited distribution. Pharmacies typically order single-vial quantities through specialty wholesalers. Verify current availability with Bausch Health Customer Service before scheduling an elective desirudin course — supply has been intermittent post-2015. For patient assistance, contact the Bausch Health Patient Assistance Program at 800-321-4576.

Old claim audits for lepirudin — what should I look for?

For retrospective audits of pre-April-2012 lepirudin claims: (1) verify the date of service predates April 2012 withdrawal; (2) confirm continuous IV infusion documentation (lepirudin label was 0.15 mg/kg/hr titrated to aPTT 1.5-2.5x baseline, with optional 0.4 mg/kg IV bolus); (3) check pharmacy dispense record substantiated by Bayer / Berlex Refludan NDC (e.g., legacy 50419-150-01); (4) confirm aPTT monitoring (q4-6h initially) is documented; (5) verify D69.5 (drug-induced thrombocytopenia) or equivalent thrombocytopenia code — the post-FY2021 HIT-specific D75.82 did not exist at the time, so earlier claims will use D69.59 or D69.6. HCPCS coding for lepirudin historically appeared under J3490 unclassified with NDC and invoice on paper, as no permanent J-code was ever assigned.

Pediatric DTI use — which legacy DTI is appropriate?

None of the three drugs on this page has a robust pediatric label. Desirudin and lepirudin have no pediatric dosing in their FDA labels. Fondaparinux has very limited pediatric data and is not labeled below age 17. For pediatric HIT, argatroban is the de facto first-line non-heparin anticoagulant — the FDA label includes a pediatric seriously-ill HIT starting dose of 0.75 mcg/kg/min. For pediatric VTE prophylaxis or treatment outside the HIT setting, current pediatric hematology practice favors enoxaparin or oral DOACs (with pediatric dosing now in the dabigatran and rivaroxaban labels) over parenteral DTIs. See /drugs/argatroban for full pediatric HIT dosing.

Pregnancy DTI selection — what is the guidance?

Desirudin and lepirudin are recombinant hirudins with limited human pregnancy data and no contemporary obstetric experience post-2012 (lepirudin) or post-DOAC era (desirudin). Fondaparinux has accumulated meaningful pregnancy case series and is the most-used non-heparin anticoagulant for pregnant patients with HIT history when heparin/LMWH cannot be used — even though HIT is contraindicated, prophylactic use in HIT-history without active HIT antibodies is in society guideline language with caveats. For active HIT in pregnancy, argatroban (Pregnancy Category B legacy) is the most-used option per CHEST 2018 — coordinate with maternal-fetal medicine and hematology and document the risk/benefit discussion in chart. See /drugs/argatroban pregnancy FAQ.

Why does this rollup exist if billers rarely see these drugs?

The page exists for defensive billing rather than acquisitional SEO. The three high-pain scenarios are: (1) a patient on Bausch Iprivask post-ortho where the J0838 line needs HIT-history or post-op encounter ICD-10 substantiation; (2) a retrospective audit hits a pre-2012 lepirudin claim and the biller needs to know lepirudin was withdrawn; and (3) the most common scenario — a fondaparinux line gets submitted under a HIT (D75.82) diagnosis and the biller needs to know fondaparinux is contraindicated in HIT and switch the patient back to argatroban or bivalirudin. The page also explains why these drugs are NOT in routine current use, which prevents billers from looking for nonexistent active-use guidance.

Source documents

1. DailyMed — desirudin (Iprivask) prescribing information
   Current FDA label, Bausch Health: 15 mg SC q12h post-elective-hip-replacement; renal dose adjustments; reconstitution instructions
2. DailyMed — fondaparinux (Arixtra) prescribing information
   Current FDA labels, GSK and generic manufacturers; HIT contraindication; weight-based treatment dosing; renal contraindication CrCl < 30; boxed warning for neuraxial anesthesia
3. FDA Drugs@FDA — desirudin NDA 21-271 (Iprivask)
   Original FDA approval record (April 2003); subsequent license-holder transfers
4. FDA Drugs@FDA — fondaparinux NDA 21-345 (Arixtra)
   Original FDA approval record (December 2001)
5. FDA — market withdrawal notices and drug shortages database
   Lepirudin / Refludan withdrawal notice, April 2012; Bayer / Berlex market exit confirmation
6. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
   ASH 2018 HIT guidelines — argatroban and bivalirudin as first-line non-heparin anticoagulants; fondaparinux as controversial off-label option only
7. CHEST / ACCP — Treatment and Prevention of Heparin-Induced Thrombocytopenia (9th ed. + 2018 update)
   Foundational HIT treatment guidelines; argatroban / bivalirudin dosing; fondaparinux contraindication discussion
8. CMS — Medicare Part B Drug ASP Pricing File (Q2 2026)
   Quarterly ASP+6% pricing for J1652. J0838 not currently published in the public ASP file as of Q2 2026 — verify with MAC.
9. CMS HCPCS Level II Quarterly Updates
   Quarterly HCPCS bulletins documenting J0838 and J1652 permanent code status
10. FDA National Drug Code Directory — desirudin, fondaparinux, lepirudin NDCs
    Manufacturer-specific 10/11-digit NDCs for Bausch Iprivask, Mylan/Viatris Arixtra, generic fondaparinux; legacy Bayer Refludan NDC
11. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
    Single-dose container drug discard reporting requirements
12. CMS — ICD-10-CM (FY2026)
    D75.82 HIT; Z86.79 HIT history; Z47.1 / Z96.64x post-hip-replacement; I82/I26 DVT/PE; D69.5 secondary thrombocytopenia
13. UnitedHealthcare — Medical Drug Coverage Policies
    Outpatient drug coverage, PA, step therapy for anticoagulant class
14. Aetna Clinical Policy Bulletins — HIT (CPB 0451) and anticoagulant policies

About this page

We maintain this page as a living reference for billers, coders, and pharmacy / RC staff working with the legacy direct thrombin inhibitor class. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 22, 2026 — Initial publication. Wave 8 commodity rollup absorbing desirudin (J0838) from Wave 7D scope per the 2026-05-22 HIT-format research memo. Three-drug rollup: desirudin / Iprivask (Bausch Health) on-label post-hip-replacement DVT prophy; lepirudin / Refludan (Bayer / Berlex, withdrawn April 2012); fondaparinux / Arixtra (Mylan / Viatris and generics, J1652) with explicit HIT contraindication warning. Active HIT use cross-linked heavily to dedicated /drugs/argatroban and /drugs/bivalirudin.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File for J1652. J0838 desirudin pricing requires MAC verification as the code is not currently in the public ASP file. Payer policies are read directly from each payer's published medical policy documents. Dosing and contraindications are verified against the FDA prescribing information and the ASH / CHEST HIT guidelines. We do not paraphrase from billing-software vendor blogs.